Radiopharmaceutical Deal Benchmarks

Radiopharmaceuticals have emerged as one of the fastest-growing modalities in oncology deal-making. Phase 1 radiopharmaceutical deals carry a median total deal value of $1.5B, with upfronts averaging $148M. The significant premium reflects constrained supply of radioisotopes, specialized manufacturing requirements, and the theranostic potential that enables patient selection via companion diagnostics.

The milestone structure for radiopharmaceutical deals allocates $531M to development milestones, recognizing the significant de-risking needed around dosimetry, manufacturing scale-up, and supply chain security for isotopes such as actinium-225 and lutetium-177. Commercial milestones of $332M reward the blockbuster trajectory demonstrated by approved RPTs.

Royalty rates range from 10% to 17.5%, with high-tier escalation to 21.5%. The constrained competitive landscape and high barriers to entry for radiopharmaceutical manufacturing give licensors strong negotiating leverage in these transactions.